EAGLE PHARMACEUTICALS INC (EGRX)
US2697961082 - Common Stock
| TTM (2023-6-30) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES | ||||||||
| Net Income | 11.94M | 35.64M | -8.63M | 11.99M | 14.31M | |||
| Depreciation Amortization | 20.62M | 12.03M | 3.76M | 3.54M | 4.65M | |||
| Income Taxes - Deferred | -7.84M | -8.32M | -3.62M | -1.51M | 150.00K | |||
| Change In Working Capital | -57.63M | -16.40M | 9.54M | 820.00K | 14.39M | |||
| Interest Paid | 4.06M | 1.73M | 1.20M | 2.22M | 2.48M | |||
| Taxes Paid | 37.20M | 28.41M | 10.01M | 6.43M | 6.67M | |||
| Other non cash items | 23.59M | 27.76M | 27.17M | 34.67M | 22.48M | |||
| OPERATING CASH FLOW | -9.32M | 50.70M | 28.22M | 49.50M | 55.99M | |||
| CASH FLOWS FROM INVESTING ACTIVITIES | ||||||||
| Capital Expenditure | -70.00K | -180.00K | -320.00K | -750.00K | -780.00K | |||
| Other Investing Activity | -23.73M | -86.65M | -5.00M | -17.50M | N/A | |||
| INVESTING CASH FLOW | -23.81M | -86.83M | -5.32M | -18.25M | -780.00K | |||
| CASH FLOWS FROM FINANCING ACTIVITIES | ||||||||
| Debt Issued/Reduced | 24.26M | 12.76M | -8.00M | -5.00M | -6.00M | |||
| Stock Issued/Repurchased | -9.71M | -16.26M | -18.82M | -31.35M | -17.70M | |||
| Other Financing Activity | -2.65M | -2.72M | -1.58M | -1.53M | -520.00K | |||
| FINANCING CASH FLOW | 11.92M | -6.21M | -28.39M | -37.87M | -24.23M | |||
| CHANGE IN CASH | -21.21M | -42.34M | -5.49M | -6.62M | 30.98M | |||
| FREE CASH FLOW | ||||||||
| Operating Cash Flow | -9.32M | 50.70M | 28.22M | 49.50M | 55.99M | |||
| Capital Expenditure | -70.00K | -180.00K | -320.00K | -750.00K | -780.00K | |||
| FREE CASH FLOW | -9.39M | 50.52M | 27.90M | 48.75M | 55.21M | |||
All data in USD